Literature DB >> 12644450

Sepsis-induced muscle growth hormone resistance occurs independently of STAT5 phosphorylation.

Ly Q Hong-Brown1, C Randell Brown, Robert N Cooney, Robert A Frost, Charles H Lang.   

Abstract

Growth hormone (GH) stimulates insulin-like growth factor I (IGF-I) synthesis in both liver and muscle. During sepsis, proinflammatory cytokines inhibit GH action in liver, but it is unknown whether sepsis also produces GH resistance in muscle. Sepsis was induced by cecal ligation and puncture, and 18 h later the effect of GH on signal transducer and activator of transcription (STAT) phosphorylation and IGF-I mRNA content was assessed in rat gastrocnemius and liver. The relative abundance of phosphorylated (p)STAT5a, pSTAT5b, pSTAT3, and pSTAT1 was increased in liver from control rats after GH. Sepsis alone also increased hepatic pSTAT5a, pSTAT3, and pSTAT1. Sepsis dramatically impaired the ability of GH to stimulate the phosphorylation of STAT5a and -5b, as well as to increase IGF-I mRNA in liver. In muscle from control rats, GH increased pSTAT5a and -5b, whereas content of pSTAT3 and pSTAT1 was not affected. Sepsis increased basal content of pSTAT3 but not pSTAT5a, pSTAT5b, or pSTAT1 in muscle. The GH-induced increase of pSTAT5a and -5b in muscle from septic rats was not inhibited, suggesting that muscle was not GH resistant. In contrast to these changes in pSTAT5, the ability of GH to increase IGF-I mRNA was completely absent in muscle from septic rats. Because the suppressor of cytokine signaling (SOCS) proteins may function as negative regulators of GH signaling, we examined the content of these proteins. Sepsis produced small (30-50%), albeit statistically significant, increases in SOCS-1, -2, and -3 protein in muscle. In contrast to muscle, the SOCS proteins in the liver did not change under the various experimental conditions, suggesting that these proteins are not responsible for the impaired phosphorylation of STAT5 by GH. In conclusion, sepsis produces GH resistance in both muscle and liver, with the locus of this impairment in muscle differing from that in liver and being independent of a defect in STAT5 phosphorylation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12644450     DOI: 10.1152/ajpendo.00555.2002

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  7 in total

1.  Hepatic growth hormone resistance after acute injury.

Authors:  Ryan M Corrick; Li Li; Stuart J Frank; Joseph L Messina
Journal:  Endocrinology       Date:  2013-02-15       Impact factor: 4.736

2.  Endotoxin-induced growth hormone resistance in skeletal muscle.

Authors:  Yu Chen; Sumita Sood; Vidya M R Krishnamurthy; Peter Rotwein; Ralph Rabkin
Journal:  Endocrinology       Date:  2009-05-14       Impact factor: 4.736

3.  Endotoxin-induced proteolytic reduction in hepatic growth hormone (GH) receptor: a novel mechanism for GH insensitivity.

Authors:  Xiangdong Wang; Jing Jiang; Jason Warram; Gerhard Baumann; Yujun Gan; Ram K Menon; Lee A Denson; Kurt R Zinn; Stuart J Frank
Journal:  Mol Endocrinol       Date:  2008-03-06

Review 4.  Cytokine inhibition of JAK-STAT signaling: a new mechanism of growth hormone resistance.

Authors:  Charles H Lang; Ly Hong-Brown; Robert A Frost
Journal:  Pediatr Nephrol       Date:  2004-11-10       Impact factor: 3.714

Review 5.  Classical and novel GH receptor signaling pathways.

Authors:  Stuart J Frank
Journal:  Mol Cell Endocrinol       Date:  2020-08-22       Impact factor: 4.102

Review 6.  Sepsis as a Pan-Endocrine Illness-Endocrine Disorders in Septic Patients.

Authors:  Weronika Wasyluk; Martyna Wasyluk; Agnieszka Zwolak
Journal:  J Clin Med       Date:  2021-05-12       Impact factor: 4.241

7.  Disruption of genes encoding eIF4E binding proteins-1 and -2 does not alter basal or sepsis-induced changes in skeletal muscle protein synthesis in male or female mice.

Authors:  Jennifer L Steiner; Anne M Pruznak; Gina Deiter; Maithili Navaratnarajah; Lydia Kutzler; Scot R Kimball; Charles H Lang
Journal:  PLoS One       Date:  2014-06-19       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.